Clinical Impact and Cost-effectiveness of Everolimus Combination Therapy in Liver Transplant Recipients: Focus on the Risk of Cancer, Infection, and Renal Function

Key Points

• This research investigates the cost-effectiveness and clinical impact of using everolimus in liver transplant recipients, focusing on cancer and infection risks.
• Evaluated cost-effectiveness of everolimus combined with CNI in liver transplant recipients.
• Assessed outcomes including cancer incidence, posttransplant infections, and renal function.
• Everolimus combination therapy proved cost-effective across multiple outcomes.
• The regimen supported risk-benefit balance for cancer, infection, and renal health.